Key Highlights
- NeOnc Technologies (NASDAQ:NTHI) closed at USD 4.47 on Tuesday, November 10, 2026, up 19.52% from a calculated prior close of USD 3.74, among the top gainers in a published screener snapshot of 4,625 names.
- Volume was 129.08K shares, a relative Volume of 1.04, so the rally came on roughly normal activity worth about USD 576,988 at the closing price (calculated).
- The snapshot shows trailing diluted EPS of USD -1.95, EPS growth of +33.60%, no P/E, a Dividend Yield of 0.00% and a Market Value of USD 128.96 million.
- Published coverage shows the chief executive bought 40,000 shares at an average USD 3.39 on November 6, 2026, a purchase worth USD 135,600, lifting his holding to 3,253,000 shares.
What Moved NeOnc Technologies on November 10 (+19.52%)
The clinical-stage biotechnology company ended the regular session at USD 4.47, up 19.52%. Simple arithmetic gives a calculated prior close of about USD 3.74 for Monday, November 9, 2026, a gain of roughly USD 0.73 per share. Published coverage put Monday's opening price at USD 3.49, so the stock was already trading near its 50-day Moving Average of USD 3.33 before the rally. The session's close of USD 4.47 sits well below the 200-day moving average of USD 5.38 and inside a one-year range of USD 2.50 to USD 12.00, about 63% below the top of that range (calculated). Volume of 129.08K shares at a relative volume of 1.04 means turnover was close to its recent average.
The Rationale: No Catalyst Identified, Insider Buying and Earnings Context
No company release, filing or trial announcement dated November 9 or 10, 2026 was identified in published coverage, so the rationale is no catalyst identified in published coverage. Context from the prior week is relevant. The company reported results on November 5, 2026 with a loss of USD 0.28 per share against a consensus estimate of a USD 0.25 loss. The chief executive then bought shares on November 6, and further Form 4 filings were reported around November 9. Analysts are split: coverage lists 4 buy, 1 hold and 1 sell ratings, with a consensus target of USD 16.00 and a BTIG target of USD 15.00 set on September 8. As general context, small biotech stocks often rally on insider purchases, upgrades or sector flows, but these are general mechanisms, not confirmed causes.
Valuation, Liquidity and Risks for NeOnc Technologies
Valuation rests on few measures. There is no P/E because trailing diluted EPS is USD -1.95, although the loss narrowed, with EPS growth of +33.60%. The dividend yield is 0.00%. A market value of USD 128.96 million implies about 28.85 million shares at USD 4.47 (calculated). Turnover of about USD 576,988 is small for a company of that size, so a small number of trades can move the price and spreads can be wide. Risks include continued losses, the need to raise Capital for clinical programs, dilution from future share sales, trial outcomes and a share price that remains far below its USD 12.00 yearly high. Insider purchases do not guarantee future gains. Nothing here implies the move will continue.
Where Things Stand
NeOnc Technologies (NASDAQ:NTHI) gained 19.52% to USD 4.47 on November 10, 2026, and no company news explains the move in published coverage. The gain came on 129.08K shares, a relative volume of 1.04, from a calculated prior close of USD 3.74. Trailing EPS is USD -1.95, there is no dividend, and the market value is USD 128.96 million. Recent insider buying of 40,000 shares at USD 3.39 is context, not a confirmed cause.






Please wait processing your request...